Indication
Relapsed Rhabdomyosarcoma
1 clinical trial
1 product
Clinical trial
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
C7R-GD2.CART cells